Skip to main content
Caplight Logo









Nanoligent

Nanoligent

Private
BarcelonaHealthcare & Life Scienceshttps://www.nanoligent.com/

Last Round

Series A

Oct 6, 2025

Total Funding Raised

$16.59M

Company Overview

Nanoligent is a biotechnology company that develops nanotechnology-based anti-cancer treatments intended to treat different types of metastatic cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

nanomedicinetargeted oncologyprecision medicineprotein-drug nanoconjugateCXCR4 receptormetastatic cancer treatmentnanobiotechnologydrug discoverybiotech licensingtargeted therapyprotein engineeringsmart drugspreclinical biotechdrug delivery platformcancer nanotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nanoligent Comparables

Compare Nanoligent with similar companies based on industry and business-model similarity.

Nanoligent comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Mainline Biosciences
78%
Cybrexa Therapeutics
76%
Polar NanoPharma
76%

Nanoligent Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AOct 6, 2025
GrantJun 19, 2025
AcceleratorNov 21, 2023
SeedSep 27, 2022
GrantDec 13, 2018

Key People

Founding team and executive leadership

Montserrat Cano Biosca

Chief Executive Officer

Executive Team

Nanoligent Investors

Notable investors and investment history

Nanoligent investors
InvestorRounds
InvereadySeries A
Avanteca PartnersSeed, Series A
Clave CapitalSeries A
Center for Technological Development and InnovationSeries A
i&i PragueSeed
DoorwaySeed, Series A
Italian Angels for GrowthSeed, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 18, 2026

    Monthly visitors grew 243% MoM.

  • Jun 19, 2025

    Won the Santander X Award 2025 for Best University Start-up.

Recent news

Latest coverage and updates

  • recognized_asJul 9, 2026

    Nanoligent SL recognized as one of the ten most disruptive companies in Catalonia for 2026 at eighth Exponential Day on Jul 9th '26.

Nanoligent Filings

Explore SEC and related filing metadata, where available.

Nanoligent filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Nanoligent's valuation, stock price, and market status.

Is Nanoligent a public or private company?

Nanoligent is a private company.

What is the current stock price of Nanoligent?

Nanoligent is a private company with no public stock price. No recent secondary market data is available.

How much is Nanoligent worth (valuation)?

Valuation information for Nanoligent is not publicly available.

Can I buy Nanoligent stock?

Nanoligent shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Nanoligent's last funding round?

Nanoligent's most recent funding round was Grant on June 19, 2025.

Who are the main investors in Nanoligent?

Key investors in Nanoligent include i&i Prague.

Will Nanoligent IPO soon?

No public IPO plans have been announced for Nanoligent.

How can I track Nanoligent secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Nanoligent's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBarcelona
Employee Range16
Year Founded2017
Last FundingOct 6, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?